Cargando…
Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.
We review pharmacokinetic and pharmacodynamic factors that should be considered in the design and interpretation of developmental neurotoxicity studies. Toxicologic effects on the developing nervous system depend on the delivered dose, exposure duration, and developmental stage at which exposure occ...
Autores principales: | Dorman, D C, Allen, S L, Byczkowski, J Z, Claudio, L, Fisher, J E, Fisher, J W, Harry, G J, Li, A A, Makris, S L, Padilla, S, Sultatos, L G, Mileson, B E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1240547/ https://www.ncbi.nlm.nih.gov/pubmed/11250810 |
Ejemplares similares
-
Methods to identify and characterize developmental neurotoxicity for human health risk assessment: overview.
por: Mileson, B E, et al.
Publicado: (2001) -
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
por: Rizk, M. L., et al.
Publicado: (2019) -
Methods to identify and characterize developmental neurotoxicity for human health risk assessment. I: behavioral effects.
por: Cory-Slechta, D A, et al.
Publicado: (2001) -
Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013) -
Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
por: Leung, Elizabeth, et al.
Publicado: (2021)